Mechanisms of action of second generation antipsychotic drugs in schizophrenia: Insights from brain imaging studies

European Psychiatry

Volumn 20, Issue 1, 2005, Pages 15-27

  Abi Dargham, Anissa ^a   Laruelle, Marc ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Antipsychotic drugs; Dopamine; Glutamate; PET; Schizophrenia; SPECT

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; AMISULPRIDE; ARIPIPRAZOLE; CATECHOL METHYLTRANSFERASE INHIBITOR; CLOZAPINE; CYCLOSERINE; DEXTRO SERINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; GLUTAMIC ACID; GLYCINE; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; NEUROTRANSMITTER; NORADRENALIN UPTAKE INHIBITOR; OLANZAPINE; PARTIAL AGONIST; QUETIAPINE; RISPERIDONE; SEROTONIN 1A AGONIST; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; TRACER; ZIPRASIDONE;

BINDING AFFINITY; CLINICAL TRIAL; DISEASE EXACERBATION; DOPAMINERGIC TRANSMISSION; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; HUMAN; MESOLIMBIC DOPAMINERGIC SYSTEM; META ANALYSIS; NEUROIMAGING; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; REVIEW; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 11844286960     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2004.11.003     Document Type: Article

References (166)

1. A. Abi-Dargham, R. Gil, J. Krystal, R.M. Baldwin, J.P. Seibyl, and M. Bowers Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort Am. J. Psychiatry 155 1998 761 767
2. 2 receptors by dopamine in schizophrenia Proc. Natl. Acad. Sci. USA 97 2000 8104 8109
3. 1 receptors and working memory in schizophrenia J. Neurosci. 22 2002 3708 3719
4. 1 receptor agonism in the prefrontal cortex as the code to decipher a Rosetta stone of antipsychotic drugs Pharmacol. Toxicol. 84 1999 193 196
5. M. Akil, J.N. Pierri, R.E. Whitehead, C.L. Edgar, C. Mohila, and A.R. Sampson Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects Am. J. Psychiatry 156 1999 1580 1589
6. N.E. Anden Dopamine turnover in the corpus striatum and the lumbic system after treatment with neuroleptic and anti-acetylcholine drugs J. Pharm. Pharmacol. 24 1972 905 906
7. N. Anden, and G. Stock Effect of clozapine on the turnover of dopamine in the corpus striatum and in the limbic system J. Pharm. Pharmacol. 25 1973 346 348
8. B. Angrist, and D.P. Van Kammen CNS stimulants as a tool in the study of schizophrenia Trends Neurosci. 7 1984 388 390
9. J. Arnt, and T. Skarsfeldt Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence Neuropsychopharmacology 18 1998 63 101
10. R.J. Baldessarini, and F.R. Frankenburg Clozapine. A novel antipsychotic agent N. Engl. J. Med. 324 1991 746 754
11. A. Bertolino, A. Breier, J.H. Callicott, C. Adler, V.S. Mattay, and M. Shapiro The relationship between dorsolateral prefrontal neuronal N-acetylaspartate and evoked release of striatal dopamine in schizophrenia Neuropsychopharmacology 22 2000 125 132
12. 123I]epidepride single photon emission tomography (SPET) study Br. J. Psychiatry 175 1999 231 238
13. 123I]epidepride single photon emission tomography (SPET) study Psychopharmacology (Berlin) 150 2000 132 140
14. A. Breier, T.P. Su, R. Saunders, R.E. Carson, B.S. Kolachana, and A. Debartolomeis Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method Proc. Natl. Acad. Sci. USA 94 1997 2569 2574
15. 123I]epidepride SPET study J. Clin. Psychopharmacol. 23 2003 5 14
16. 123I]epidepride SPET study of amisulpride-treated patients Am. J. Psychiatry 160 2003 1413 1420
17. A. Carlsson, and M. Lindqvist Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain Acta Pharmacol. Toxicol. (Copenh.) 20 1963 140 144
18. W.T. Carpenter, and R.W. Buchanan Schizophrenia N. Engl. J. Med. 330 1994 681 690
19. D. Centonze, B. Picconi, P. Gubellini, G. Bernardi, and P. Calabresi Dopaminergic control of synaptic plasticity in the dorsal striatum Eur. J. Neurosci. 13 2001 1071 1077
20. C. Cepeda, and M.S. Levine Dopamine and N-methyl-d-aspartate receptor interactions in the neostriatum Dev. Neurosci. 20 1998 1 8
21. 2 dopamine receptor-deficient mice J. Neurophysiol. 85 2001 659 670
22. L. Chiodo, and B. Bunney Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons J. Neurosci. 3 1983 1607 1609
23. I. Creese, D.R. Burt, and S.H. Snyder Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs Science 19 1976 481 483
24. 1 receptors using an antibody capture assay: antagonist properties of clozapine Eur. J. Pharmacol. 485 2004 111 117
25. D.G. Daniel, D.R. Weinberger, D.W. Jones, J.R. Zigun, R. Coppola, and S. Handel The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia J. Neurosci. 11 1991 1907 1917
26. M.H. Dao-Castellana, M.L. Paillere-Martinot, P. Hantraye, D. Attar-Levy, P. Remy, and C. Crouzel Presynaptic dopaminergic function in the striatum of schizophrenic patients Schizophr. Res. 23 1997 167 174
27. K.L. Davis, R.S. Kahn, G. Ko, and M. Davidson Dopamine in schizophrenia: a review and reconceptualization Am. J. Psychiatry 148 1991 1474 1486
28. J.M. Davis, N. Chen, and I.D. Glick A meta-analysis of the efficacy of second-generation antipsychotics Arch. Gen. Psychiatry 60 2003 553 564
29. 1 antagonist SCH 39166 in six cases of acute psychotic states Psychopharmacology (Berlin) 121 1995 323 327
30. T. de Paulis M-100907 (Aventis) Curr. Opin. Invest. Drugs 2 2001 123 132
31. B. Dean, and E. Scarr Antipsychotic drugs: evolving mechanisms of action with improved therapeutic benefits Curr. Drug Targets CNS Neurol. Disord. 3 2004 217 2175
32. J. Delay, P. Deniker, and J.M. Harl Therapeutic use in psychiatry of phenothiazine of central elective action (4560 RP) Ann. Med. Psychol. (Paris) 1952 112 117
33. A. DeLeon, N.C. Patel, and M.L. Crismon Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability Clin. Ther. 26 2004 649 656
34. 1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia Psychopharmacology (Berlin) 121 1995 317 322
35. A.Y. Deutch, W.A. Clark, and R.H. Roth Prefrontal cortical dopamine depletion enhances the responsiveness of mesolimbic dopamine neurons to stress Brain Res. 521 1990 311 315
36. A.Y. Deutch, B. Moghadam, R. Innis, J. Krystal, G. Aghajanian, and B. Bunney Mechanisms of action of atypical antipsychotic drugs. Implication for novel therapeutic strategies for schizophrenia Schizophr. Res. 4 1991 21 56
37. A.Y. Deutch, M.C. Lee, and M.J. Iadarola Regionally specific effects of atypical antipsychotic drugs on striatal fos expression: the nucleus accumbens shell as a locus of antipsychotic action Mol. Cell. Neurosci. 3 1992 332 341
38. R.J. Dolan, P. Fletcher, C.D. Frith, K.J. Friston, R.S. Frackowiak, and P.M. Grasby Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia Nature 378 1995 180 182
39. 1 receptor-dependent trafficking of striatal NMDA glutamate receptors to the postsynaptic membrane J. Neurosci. 21 2001 5546 5548
40. G.E. Duncan, S. Zorn, and J.A. Lieberman Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia Mol. Psychiatry 4 1999 418 428
41. 2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs Arch. Gen. Psychiatry 45 1988 71 76
42. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine Arch. Gen. Psychiatry 49 1992 538 544
43. 1 receptors and DARPP-32 J. Neurophysiol. 88 2002 3010 3020
44. W.G. Frankle, J. Lerma, and M. Laruelle The synaptic hypothesis of schizophrenia Neuron 39 2003 205 216
45. 2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications Psychopharmacology (Berlin) 2004 In press
46. J.I. Friedman, H. Temporini, and K.L. Davis Pharmacologic strategies for augmenting cognitive performance in schizophrenia Biol. Psychiatry 45 1999 1 6
47. J. Geddes, N. Freemantle, P. Harrison, and P. Bebbington Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis BMJ 321 2000 1371 1376
48. O. Gefvert, M. Bergstrom, B. Langstrom, T. Lundberg, L. Lindstrom, and R. Yates Time course of central nervous dopamine-D-2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel(R)) in patients with schizophrenia Psychopharmacology (Berl.) 135 1998 119 126
49. G.L. Gessa, P. Devoto, M. Diana, G. Flore, M. Melis, and M. Pistis Dissociation of haloperidol, clozapine, and olanzapine effects on electrical activity of mesocortical dopamine neurons and dopamine release in the prefrontal cortex Neuropsychopharmacology 22 2000 642 649
50. D.C. Goff, and J.T. Coyle The emerging role of glutamate in the pathophysiology and treatment of schizophrenia Am. J. Psychiatry 158 2001 1367 1377
51. D.C. Goff, G. Tsai, J. Levitt, E. Amico, D. Manoach, and D.A. Schoenfeld A placebo-controlled trial of d-cycloserine added to conventional neuroleptics in patients with schizophrenia Arch. Gen. Psychiatry 56 1999 21 27
52. P.S. Goldman-Rakic, E.C. Muly 3rd, and G.V. Williams D(1) receptors in prefrontal cells and circuits Brain Res. Brain Res. Rev. 31 2000 295 301
53. A.A. Grace Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia Neuroscience 41 1991 1 24
54. A.A. Grace, B.S. Bunney, H. Moore, and C.L. Todd Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs Trends Neurosci. 20 1997 31 37
55. A.M. Graybiel The basal ganglia and cognitive pattern generators Schizophr. Bull. 23 1997 459 469
56. 1 radioligands: implication for imaging studies in schizophrenia Neuropsychopharmacology 28 2003 1703 1711
57. P.J. Harrison, and D.R. Weinberger Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence Mol. Psychiatry 2004 In press
58. U. Heresco-Levy Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality Prog. Neuropsychopharmacol. Biol. Psychiatry 27 2003 1113 1123
59. U. Heresco-Levy, D.C. Javitt, M. Ermilov, G. Silipo, and J. Shimoni Double-blind, placebo-controlled, crossover trial of d-cycloserine adjuvant therapy for treatment-resistant schizophrenia Int. J. Neuropsychopharmacol. 1 1998 131 136
60. U. Heresco-Levy, D.C. Javitt, M. Ermilov, C. Mordel, G. Silipo, and M. Lichtenstein Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia Arch. Gen. Psychiatry 56 1999 29 36
61. U. Heresco-Levy, M. Ermilov, J. Shimoni, B. Shapira, G. Silipo, and D.C. Javitt Placebo-controlled trial of d-cycloserine added to conventional neuroleptics, olanzapine and risperidone in schizophrenia Am. J. Psychiatry 159 2002 480 482
62. 2+ conductance J. Neurosci. 17 1997 3334 3342
63. J. Hietala, E. Syvalahti, K. Vuorio, V. Rakkolainen, J. Bergman, and M. Haaparanta Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients Lancet 346 1995 1130 1131
64. J. Hietala, E. Syvalahti, H. Vilkman, K. Vuorio, V. Rakkolainen, and J. Bergman Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia Schizophr. Res. 35 1999 41 50
65. H. Hippius A historical perspective of clozapine J. Clin. Psychiatry 60 1999 S22 S23
66. J. Ichikawa, H. Ishii, S. Bonaccorso, W.L. Fowler, I.A. O'Laughlin, and H.Y. Meltzer 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release J. Neurochem. 76 2001 1521 1531
67. J. Ichikawa, J. Dai, I.A. O'Laughlin, W.L. Fowler, and H.Y. Meltzer Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum Neuropsychopharmacology 26 2002 325 329
68. J. Idanpaan-Heikkila, E. Alhava, M. Olkinuora, and I.P. Palva Agranulocytosis during treatment with clozapine Eur. J. Clin. Pharmacol. 11 1977 193 198
69. 2 receptors? Psychopharmacology (Berlin) 138 1998 213 216
70. D.C. Javitt, and S.R. Zukin Recent advances in the phencyclidine model of schizophrenia Am. J. Psychiatry 148 1991 1301 1308
71. D.C. Javitt, I. Zylberman, S.R. Zukin, U. Heresco-Levy, and J.P. Lindenmayer Amelioration of negative symptoms in schizophrenia by glycine Am. J. Psychiatry 151 1994 1234 1236
72. D.C. Javitt, G. Silipo, A. Cienfuegos, A.M. Shelley, N. Bark, and M. Park Adjunctive high-dose glycine in the treatment of schizophrenia Int. J. Neuropsychopharmacol. 4 2001 385 391
73. J.D. Jentsch, and R.H. Roth The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia Neuropsychopharmacology 20 1999 201 205
74. R.S. Kahn, P.D. Harvey, M. Davidson, R.S. Keefe, S. Apter, and J.M. Neale Neuropsychological correlates of central monoamine function in chronic schizophrenia: relationship between CSF metabolites and cognitive function Schizophr. Res. 11 1994 217 224
75. J. Kane, G. Honigfeld, J. Singer, and H.Y. Meltzer Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine Arch. Gen. Psychiatry 45 1988 789 796
76. 2 receptors. Implications for atypical antipsychotic action J. Psychiatry Neurosci. 25 2000 161 166
77. S. Kapur, and P. Seeman Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis Am. J. Psychiatry 158 2001 360 369
78. 2 receptor occupancy of olanzapine in schizophrenia: a PET investigation Am. J. Psychiatry 155 1998 921 928
79. 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia Am. J. Psychiatry 156 1999 286 293
80. S. Kapur, R. Zipursky, C. Jones, G. Remington, and S. Houle Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia Am. J. Psychiatry 157 2000 514 520
81. 1 receptor antagonist, in the treatment of schizophrenia Psychopharmacology (Berlin) 121 1995 328 329
82. 1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients Psychopharmacology (Berlin) 121 1995 309 316
83. P. Karlsson, L. Farde, C. Halldin, and G. Sedvall PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia Am. J. Psychiatry 159 2002 761 767
84. M.B. Knable, and D.R. Weinberger Dopamine, the prefrontal cortex and schizophrenia J. Psychopharmacol. 11 1997 123 131
85. B.S. Kolachana, R.C. Saunders, J. Bachevalier, and D.R. Weinberger Abnormal prefrontal cortical regulation of striatal dopamine release after neonatal medial temporal-limbic lesions in rhesus monkeys Soc. Neurosci. 1996 Abst. 22:1974
86. C. Konradi, and S. Heckers Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment Pharmacol. Ther. 97 2003 153 179
87. R. Kotter Postsynaptic integration of glutamatergic and dopaminergic signals in the striatum Prog. Neurobiol. 44 1994 163 196
88. J.H. Krystal, L.P. Karper, J.P. Seibyl, G.K. Freeman, R. Delaney, and J.D. Bremner Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses Arch. Gen. Psychiatry 51 1994 199 214
89. B. Kufferle, J. Tauscher, S. Asenbaum, C. Vesely, I. Podreka, and T. Brücke IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol Psychopharmacology (Berl.) 133 1997 323 328
90. A.C. Lahti, B. Koffel, D. LaPorte, and C.A. Tamminga Subanesthetic doses of ketamine stimulate psychosis in schizophrenia Neuropsychopharmacology 13 1995 9 19
91. A.C. Lahti, M.A. Weiler, B.A. Tamara Michaelidis, A. Parwani, and C.A. Tamminga Effects of ketamine in normal and schizophrenic volunteers Neuropsychopharmacology 25 2001 455 467
92. M. Laruelle Dopamine transmission in the schizophrenic brain D.R. Weinberger S. Hirsch Schizophrenia, 2nd ed 2003 Blackwell Publishing Oxford, UK 365 387
93. M. Laruelle, A. Abi-Dargham, C.H. Van Dyck, R. Gil, C.D. De Souza, and J. Erdos Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug free schizophrenic subjects Proc. Natl. Acad. Sci. USA 93 1996 9235 9240
94. M. Laruelle, A. Abi-Dargham, R. Gil, L. Kegeles, and R. Innis Increased dopamine transmission in schizophrenia: relationship to illness phases Biol. Psychiatry 46 1999 56 72
95. J.C. Leveque, W. Macias, A. Rajadhyaksha, R.R. Carlson, A. Barczak, and S. Kang Intracellular modulation of NMDA receptor function by antipsychotic drugs J. Neurosci. 20 2000 4011 4020
96. M.S. Levine, Z. Li, C. Cepeda, H.C. Cromwell, and K.L. Altemus Neuromodulatory actions of dopamine on synaptically-evoked neostriatal responses in slices Synapse 24 1996 65 78
97. T.I. Lidsky Reevaluation of the mesolimbic hypothesis of antipsychotic drug action Schizophr. Bull. 21 1995 67 74
98. J.A. Lieberman, J.M. Kane, and J. Alvir Provocative tests with psychostimulant drugs in schizophrenia Psychopharmacology (Berl.) 91 1987 415 433
99. L.H. Lindstrom, O. Gefvert, G. Hagberg, T. Lundberg, M. Bergstrom, and P. Hartvig Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by l-(beta-11C) DOPA and PET Biol. Psychiatry 46 1999 681 688
100. O. Lindvall, and A. Björklund Dopamine- and norepinephrine- containing neuron systems: their anatomy in the rat brain P. Emson Chemical neuroanatomy 1983 Raven Press New York 229 255
101. 2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone Am. J. Psychiatry 161 2004 818 825
102. 2 receptors J. Neurochem. 83 2002 635 644
103. S. Matthysse Antipsychotic drug actions: a clue to the neuropathology of schizophrenia? Fed. Proc. 32 1973 200 205
104. S. Matthysse Dopamine and the pharmacology of schizophrenia: the state of the evidence J. Psychiatr. Res. 11 1974 107 113
105. 2 receptor parameter measurements in ventral striatum J. Cereb. Blood Flow Metab. 21 2001 1034 1057
106. 18F]fluorodopa study Arch. Gen. Psychiatry 61 2004 134 142
107. M. Melis, M. Diana, and G.L. Gessa Clozapine potently stimulates mesocortical dopamine neurons Eur. J. Pharmacol. 366 1999 R11 R13
108. H.Y. Meltzer, S. Matsubara, and J.C. Lee Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2, and serotonin 2 pki values J. Pharmacol. Exp. Ther. 251 1989 238 246
109. H.Y. Meltzer, Z. Li, Y. Kaneda, and J. Ichikawa Serotonin receptors: their key role in drugs to treat schizophrenia Prog. Neuropsychopharmacol. Biol. Psychiatry 27 2003 1159 1172
110. A. Meyer-Lindenberg, R.S. Miletich, P.D. Kohn, G. Esposito, R.E. Carson, and M. Quarantelli Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia Nat. Neurosci. 5 2002 267 271
111. S. Miyamoto, G.E. Duncan, C.E. Marx, and J.A. Lieberman Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs Mol. Psychiatry 2004 In press
112. G.J. Mogenson, D.L. Jones, and C.Y. Yim From motivation to action: functional interface between the limbic system and the motor system Prog. Neurobiol. 14 1980 69 97
113. 2 receptor antagonism differentially modulates stimulation of striatal neurotransmitter levels by N-methyl-d-aspartic acid Eur. J. Pharmacol. 256 1994 23 30
114. S.M. Nicola, J. Surmeier, and R.C. Malenka Dopaminergic modulation of neuronal excitability in the striatum and nucleus accumbens Annu. Rev. Neurosci. 23 2000 185 215
115. 2 receptors in dopamine depleted animals Psychopharmacology (Berlin) 35 1998 311 317
116. I. Ninan, and R.Y. Wang Modulation of the ability of clozapine to facilitate NMDA- and electrically evoked responses in pyramidal cells of the rat medial prefrontal cortex by dopamine: pharmacological evidence Eur. J. Neurosci. 17 2003 1306 1312
117. 2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients Biol. Psychiatry 33 1993 227 235
118. 1 receptors in schizophrenia revealed by PET Nature 385 1997 634 636
119. J.W. Olney, and N.B. Farber Glutamate receptor dysfunction and schizophrenia Arch. Gen. Psychiatry 52 1995 998 1007
120. S.P. Onn, A.R. West, and A.A. Grace Dopamine-mediated regulation of striatal neuronal and network interactions Trends Neurosci. 23 2000 S48 S56
121. M.G. Packard, and B.J. Knowlton Learning and memory functions of the basal ganglia Annu. Rev. Neurosci. 25 2002 563 593
122. C. Pantelis, and T.J. Lambert Managing patients with "treatment- resistant" schizophrenia Med. J. Aust. 178 2003 S62 S66
123. E.A. Pehek, and B.K. Yamamoto Differential effects of locally administered clozapine and haloperidol on dopamine efflux in the rat prefrontal cortex and caudate-putamen J. Neurochem. 63 1994 2118 2124
124. 3H]d-aspartate release by D-2 dopamine receptors in rat striatal slices Synapse 2 1988 450 456
125. 2 dopamine receptor occupancy in clozapine-treated patients Am. J. Psychiatry 153 1996 1571 1578
126. 2 dopamine receptor blockade hypothesis of schizophrenia Lancet 340 1992 199 202
127. L.S. Pilowsky, R.S. Mulligan, P.D. Acton, P.J. Ell, D.C. Costa, and R.W. Kerwin Limbic selectivity of clozapine Lancet 350 1997 490 491
128. C.J. Pycock, R.W. Kerwin, and C.J. Carter Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats Nature 286 1980 74 77
129. J. Reith, C. Benkelfat, A. Sherwin, Y. Yasuhara, H. Kuwabara, and F. Andermann Elevated dopa decarboxylase activity in living brain of patients with psychosis Proc. Natl. Acad. Sci. USA 91 1994 11651 11654
130. G. Remington Understanding antipsychotic "atypicality": a clinical and pharmacological moving target J. Psychiatry Neurosci. 28 2003 275 284
131. G. Remington, S. Kapur, and R. Zipursky The relationship between risperidone plasma levels and dopamine D-2 occupancy: a positron emission tomographic study J. Clin. Psychopharmacol. 18 1998 82 83
132. G. Robertson, and H. Fibiger Neuroleptics increase C-fos expression in the forebrain: contrasting effects of haloperidol and clozapine Neuroscience 46 1992 315 328
133. G.S. Robertson, H. Matsumura, and H.C. Fibiger Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity J. Pharmacol. Exp. Ther. 271 1994 1058 1066
134. H. Rollema, Y. Lu, A.W. Schmidt, and S.H. Zorn Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation Eur. J. Pharmacol. 338 1997 R3 R5
135. H. Rollema, Y. Lu, A.W. Schmidt, J.S. Sprouse, and S.H. Zorn 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex Biol. Psychiatry 48 2000 229 237
136. J.A. Saint-Cyr, A.E. Taylor, and K. Nicholson Behavior and the basal ganglia Adv. Neurol. 65 1995 1 28
137. C.B. Saper Role of the cerebral cortex and striatum in emotional motor response Prog. Brain Res. 107 1996 537 550
138. 2-dopamine receptor occupancy during treatment with typical and atypical neuroleptics Biol. Psychiatry 36 1994 627 629
139. T.F. Seeger, P.A. Seymour, A.W. Schmidt, S.H. Zorn, D.W. Schulz, and L.A. Lebel Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity J. Pharmacol. Exp. Ther. 275 1995 101 103
140. P. Seeman, and T. Lee Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons Science 188 1975 1217 1219
141. D.A. Shapiro, S. Renock, E. Arrington, L.A. Chiodo, L.X. Liu, and D.R. Sibley Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology Neuropsychopharmacology 28 2003 1400 1411
142. A.D. Smith, and J.P. Bolam The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones Trends Neurosci. 13 1990 259 265
143. S.H. Snyder Cathecolamines in the brain as mediator of amphetamine psychosis Arch. Gen. Psychiatry 27 1972 169 179
144. 2 balance in the basal ganglia and its relevance to Parkinson's disease Synapse 19 1995 264 293
145. 3 dopamine receptor occupancy by quetiapine in vivo. [(123)I]-epidepride single photon emission tomography(SPET) study Br. J. Psychiatry 177 2000 408 415
146. J. Stevens An anatomy of schizophrenia? Arch. Gen. Psychiatry 29 1973 177 189
147. M. Talvik, A.L. Nordstrom, S. Nyberg, H. Olsson, C. Halldin, and L. Farde No support for regional selectivity in clozapine-treated patients: a PET study with [(11)C]raclopride and [(11)C]FLB 457 Am. J. Psychiatry 158 2001 926 930
148. C.A. Tamminga, H.H. Holcomb, X.M. Gao, and A.C. Lahti Glutamate pharmacology and the treatment of schizophrenia: current status and future directions Int. Clin. Psychopharmacol. 3 1995 29 37
149. S. Tauscher-Wisniewski, S. Kapur, J. Tauscher, C. Jones, Z.J. Daskalakis, and G. Papatheodorou Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade J. Clin. Psychiatry 63 2002 992 997
150. G. Tsai, P. Yang, L.C. Chung, N. Lange, and J.T. Coyle D-Serine added to antipsychotics for the treatment of schizophrenia Biol. Psychiatry 44 1998 1081 1089
151. D.R. Weinberger Implications of the normal brain development for the pathogenesis of schizophrenia Arch. Gen. Psychiatry 44 1987 660 669
152. D.R. Weinberger, and M. Laruelle Neurochemical and neuropharmacological imaging in schizophrenia K.L. Davis D.S. Charney J.T. Coyle C. Nemeroff Neuropharmacology--the fifth generation of progress 2001 Lippincott, Williams and Wilkins Philadelphia, PA, USA
153. D.R. Weinberger, K.F. Berman, and R.F. Zec Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia: I. Regional Cerebral Blood flow evidence Arch. Gen. Psychiatry 43 1986 114 124
154. D.R. Weinberger, K.F. Berman, and T.N. Chase Mesocortical dopaminergic function and human cognition Ann. N. Y. Acad. Sci. 537 1988 330 338
155. 2 receptor activation on activity states and electrophysiological properties of striatal neurons: studies combining in vivo intracellular recordings and reverse microdialysis J. Neurosci. 22 2002 294 304
156. B.H. Westerink, Y. Kawahara, P. De Boer, C. Geels, J.B. De Vries, and H.V. Wikstrom Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum Eur. J. Pharmacol. 412 2001 127 138
157. F.J. White, and R.Y. Wang Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons Science 221 1983 1054 1057
158. 2-receptor occupancy during antipsychotic drug treatment Prog. Neuropsychopharmacol. Biol. Psychiatry 14 1990 759 767
159. C.J. Wilson, and Y. Kawaguchi The origins of two-state spontaneous membrane potential fluctuations of neostriatal spiny neurons J. Neurosci. 16 1996 2397 2410
160. A. Wolkin, F. Barouche, A.P. Wolf, J. Rotrosen, J.S. Fowler, and C.Y. Shiue Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia Am. J. Psychiatry 146 1989 905 908
161. X. Xiberas, J.L. Martinot, L. Mallet, E. Artiges, C. Loc'h, and B. Maziere Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia Br. J. Psychiatry 179 2001 503 508
162. X. Xiberas, J.L. Martinot, L. Mallet, E. Artiges, M. Canal, and C. Loc'h In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia J. Clin. Psychopharmacol. 21 2001 207 214
163. B.K. Yamamoto, and M.A. Cooperman Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations J. Neurosci. 14 1994 4159 4166
164. 2-dopamine receptor occupancy with risperidone Psychopharmacology (Berlin) 154 2001 112 114
165. 11C]raclopride Neuropsychopharmacology 27 2002 248 259
166. K.D. Youngren, F.M. Inglis, P.J. Pivirotto, H.P. Jedema, C.W. Bradberry, and P.S. Goldman-Rakic Clozapine preferentially increases dopamine release in the rhesus monkey prefrontal cortex compared with the caudate nucleus Neuropsychopharmacology 20 1999 403 412